Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2008, for R&R Acquisition VI, Inc. (Note: The request metadata listed "ADMA BIOLOGICS, INC.", but the filing text explicitly identifies the registrant as R&R Acquisition VI, Inc.). The company is a Delaware corporation classified as a "blank check" or development stage company. Its sole objective is to acquire or merge with an operating business. As of the reporting date, the company had not commenced any operations, had no employees, and maintained no specific business plan other than seeking a merger target.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2008 | Inception to Sep 30, 2008 |
|---|---|---|
| Revenue | $0 | $0 |
| Total Operating Expenses | $3,306 | $76,457 |
| Net Loss | $(3,302) | $(76,363) |
| Cash and Cash Equivalents | $12,745 | $12,745 |
| Working Capital | $4,387 | N/A |
| Total Liabilities | $8,358 | $8,358 |
| Stockholders' Equity (Deficit) | $4,387 | $4,387 |
Capital Structure: 2,500,000 shares of common stock outstanding. The company raised $21,000 in contributed capital during the quarter.
Material Changes vs. Prior Period
- Expenses: Total operating expenses decreased to $3,306 for the three months ended September 30, 2008, compared to $5,299 in the same period of 2007. This reduction was driven primarily by lower professional fees ($3,000 vs. $4,250) and formation costs ($306 vs. $1,049).
- Liquidity: Cash and cash equivalents increased significantly from $2,647 at June 30, 2008, to $12,745 at September 30, 2008. This increase was funded by $21,000 in contributed capital, offset by $10,902 in net cash used for operating activities.
- Liabilities: Accrued expenses decreased from $15,958 to $8,358, improving the working capital position from a deficit of $(13,311) to a positive $4,387.
Outlook, Risks, and Management Commentary
Outlook: Management states that the company has no specific business plan and no assurance that a merger or business combination will occur. The company expects to have sufficient proceeds to effect only a single business combination. Future operations are entirely dependent on the successful acquisition of a target company.
Risks and Contingencies:
- Liquidity Risk: The company has no revenue and is dependent on future loans from stockholders or management to continue operations. There is no assurance these funds will be available.
- Business Risk: As a "blank check" company, the entity is subject to state statutes limiting the sale of its securities. Success depends entirely on the future performance of a single target business, offering no diversification of risk.
- Management Continuity: Current management expects to play no managerial role following a business combination.
Unusual Items: The filing contains no unusual items; expenses are limited to professional fees and filing costs associated with maintaining public company status.
Investor Verification Checklist
- Verify the identity of the registrant (R&R Acquisition VI, Inc.) versus the metadata provided (ADMA BIOLOGICS, INC.) to ensure the correct filing is being analyzed.
- Confirm the source of the $21,000 contributed capital received during the quarter and any related agreements with stockholders.
- Assess the timeline for the company to find a merger target, given the limited cash runway ($12,745) and ongoing professional fees.
- Review the "blank check" status and associated regulatory restrictions in relevant jurisdictions.
- Check for any undisclosed agreements with prospective target companies, as none are currently disclosed.